case_images: PMC8081882_01
case_images: In patient 1, series of brain MRI revealed small and scattered lesions distributed in the pons (indicated by arrows), presenting hyperintensity on horizontal and sagittal T2-weighted images (A,B), high signal on the diffusion-weighted image (DWI) (C), and slim contrast enhancement after Gd-DTPA injection on horizontal, sagittal, and coronal position (D-F). After treatment for 6 months, follow-up MRI images were seen in the patient. Horizontal and sagittal T2-weighted images (G,H), DWI (I), Gd-DTPA enhancement on horizontal, sagittal, and coronal position (J-L), showing complete regression of lesions in the pons.
case_images: fneur-12-595984-g0001.jpg
case_images: PMC8081882_01_fneur-12-595984-g0001.jpg
case_images: F1
case_images: A series of brain MRIs revealed small and scattered lesions distributed in the pons, presenting hypointensity on T1-weighted, hyperintensity on T2-weighted images, high signals on the diffusion-weighted image (DWI), and slim contrast enhancement after Gd-DTPA injection (Figures 1A-F). A total of 6 months later, follow-up MRI images in the patient have shown complete regression of lesions in the pons (Figures 1G-L).
case_images: A peripheral blood flow cytometry immunophenotype showed depletion of CD20+ B lymphocytes in NBD patients with reduced-dosage rituximab treatment 100 mg IV once per week for 3 consecutive weeks. Peripheral blood flow cytometry immunophenotype in patient 1 before (A) and after (B) 3 weeks treatment, patient 2 before (C), and after (D) 6 weeks treatment. (E) The repopulation of CD19+ B lymphocytes in patients with NBD during rituximab therapy still remains at a lower level. (F) The lower repopulation of CD19+CD27+ B lymphocytes paralleled that of CD19+ B cells after rituximab treatment.
case_images: fneur-12-595984-g0002.jpg
case_images: PMC8081882_02_fneur-12-595984-g0002.jpg
case_images: F2
case_images: Moreover, the peripheral blood flow cytometry immunophenotype showed a normal percentage of CD3+ total T lymphocyte 68% (normal 59.4-84.6%) and elevated CD20+ B lymphocyte of 27.18% (normal 6-20%) (Figure 2C), CD19+ B lymphocyte of 27.28%, and CD19+CD27+ B lymphocyte of 3.84%. Tests of ESR, CRP, CSF protein, and white cell count were all normal, and peripheral blood flow cytometry immunophenotype showed a decreased CD20+ B lymphocyte count of 0.00% (Figure 2D), CD19+ B lymphocyte of 1.92%, and CD19+CD27+ B lymphocyte of 1.07%. Consecutive peripheral blood flow cytometry immunophenotype showed that the percentage of CD19+ B cells (<= 1%) and CD19+CD27+ B cells (<= 0.05%) still remained at the low level (Figures 2E,F).
case_images: PMC8081882_02
case_images: A peripheral blood flow cytometry immunophenotype showed depletion of CD20+ B lymphocytes in NBD patients with reduced-dosage rituximab treatment 100 mg IV once per week for 3 consecutive weeks. Peripheral blood flow cytometry immunophenotype in patient 1 before (A) and after (B) 3 weeks treatment, patient 2 before (C), and after (D) 6 weeks treatment. (E) The repopulation of CD19+ B lymphocytes in patients with NBD during rituximab therapy still remains at a lower level. (F) The lower repopulation of CD19+CD27+ B lymphocytes paralleled that of CD19+ B cells after rituximab treatment.
case_images: fneur-12-595984-g0002.jpg
case_images: PMC8081882_02_fneur-12-595984-g0002.jpg
case_images: F2
case_images: Moreover, the peripheral blood flow cytometry immunophenotype showed a normal percentage of CD3+ total T lymphocyte 68% (normal 59.4-84.6%) and elevated CD20+ B lymphocyte of 27.18% (normal 6-20%) (Figure 2C), CD19+ B lymphocyte of 27.28%, and CD19+CD27+ B lymphocyte of 3.84%. Tests of ESR, CRP, CSF protein, and white cell count were all normal, and peripheral blood flow cytometry immunophenotype showed a decreased CD20+ B lymphocyte count of 0.00% (Figure 2D), CD19+ B lymphocyte of 1.92%, and CD19+CD27+ B lymphocyte of 1.07%. Consecutive peripheral blood flow cytometry immunophenotype showed that the percentage of CD19+ B cells (<= 1%) and CD19+CD27+ B cells (<= 0.05%) still remained at the low level (Figures 2E,F).